Neurizon Therapeutics

Executive Summary

Neurizon Therapeutics is an Australian biotech company pioneering the repurposing of the anthelmintic drug S-Monepantel (NUZ-001) for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS). The company leverages adaptive platform trial designs to accelerate clinical development and regulatory approval. NUZ-001 has demonstrated preclinical promise in modulating multiple disease pathways, including neuroinflammation and protein aggregation, positioning it as a potential disease-modifying therapy for ALS and other indications such as Alzheimer's, Parkinson's, and Huntington's diseases. Neurizon's strategy aims to capitalize on the existing safety data of S-Monepantel to streamline Phase 2 development and pursue accelerated regulatory pathways.

Upcoming Catalysts (preview)

• Q3 2026Interim Data from Phase 2 Adaptive ALS Trial60% success
• Q4 2026FDA Meeting for Accelerated Approval Pathway Guidance70% success
• Q1 2027Initiation of Phase 2 Trial in Alzheimer's Disease40% success